We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last-reported quarter, the company’s earnings of $2.88 per share surpassed the Zacks Consensus Estimate by 107.2%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on two occasions and missed the same in the other two, delivering an earnings surprise of 16.6%, on average.
Let’s see how things have shaped up for MLAB prior to this announcement:
Factors to Note
Clinical Genomics
During the second-quarter fiscal 2023 earnings release in November, Mesa Laboratories’ Clinical Genomics segment (added after the completion of the acquisition of Agena Bioscience, Inc.) witnessed robust global systems placements and China revenues. This resulted from a strong rebound of these two sources in the quarter after timing issues and lockdown-related headwinds eased from the fiscal first quarter. The segment also saw strong revenue contributions (excluding COVID-19-related revenues) during its first twelve months of ownership, which was in line with the guidance provided at the time of the acquisition.
In the fiscal third quarter, the strong momentum of global systems placements is likely to have continued, thereby strongly contributing to segmental revenues.
In the second quarter of fiscal 2023, Mesa Laboratories witnessed strong bookings growth in its Sterilization and Disinfection Control segment. The segment also benefited from improving labor-based constraints in its Bozeman, MT facility. Management had confirmed during the fiscal second-quarter earnings release that strong execution of process improvement initiatives in commercial engagement, labor supply and supply-chain execution had driven its strong revenue growth and profitability improvements in the quarter. This momentum is expected to have continued in the to-be-reported quarter, thereby driving up the overall revenues.
However, the current unstable macroeconomic business environment, resulting from the supply-chain constraints, unfavorable currency movement and inflationary pressures, is likely to have weighed on the company’s fiscal third-quarter revenues, raising our apprehension.
The Estimate Picture
For third-quarter fiscal 2023, the Zacks Consensus Estimate of $57.7 million for total revenues implies an improvement of 5.5% from the prior-year quarter’s reported figure.
The consensus estimate for earnings per share is pegged at $2.10 , indicating an uptick of 54.4% from the prior-year period’s reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here, as you can see:
Earnings ESP: Mesa Laboratories has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few other medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle:
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has an Earnings ESP of +1.32% and a Zacks Rank of 2. ZBH has an estimated long-term growth rate of 7.7%.
Zimmer Biomet’s earnings surpassed estimates in three of the trailing four quarters and missed the same in the other, with the average surprise being 6.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +5.75% and is a Zacks #2 Rank stock. CAH has an estimated long-term growth rate of 11.7%.
Cardinal Health’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, with the average surprise being 3%.
IDEXX Laboratories, Inc. (IDXX - Free Report) has an Earnings ESP of +0.39% and carries a Zacks Rank of 2 at present. IDXX has an estimated long-term growth rate of 17.3%.
IDEXX’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 5.2%.
Image: Bigstock
What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?
Mesa Laboratories, Inc. (MLAB - Free Report) is scheduled to report third-quarter fiscal 2023 results on Feb 6, before market open.
In the last-reported quarter, the company’s earnings of $2.88 per share surpassed the Zacks Consensus Estimate by 107.2%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on two occasions and missed the same in the other two, delivering an earnings surprise of 16.6%, on average.
Let’s see how things have shaped up for MLAB prior to this announcement:
Factors to Note
Clinical Genomics
During the second-quarter fiscal 2023 earnings release in November, Mesa Laboratories’ Clinical Genomics segment (added after the completion of the acquisition of Agena Bioscience, Inc.) witnessed robust global systems placements and China revenues. This resulted from a strong rebound of these two sources in the quarter after timing issues and lockdown-related headwinds eased from the fiscal first quarter. The segment also saw strong revenue contributions (excluding COVID-19-related revenues) during its first twelve months of ownership, which was in line with the guidance provided at the time of the acquisition.
In the fiscal third quarter, the strong momentum of global systems placements is likely to have continued, thereby strongly contributing to segmental revenues.
Mesa Laboratories, Inc. Price and EPS Surprise
Mesa Laboratories, Inc. price-eps-surprise | Mesa Laboratories, Inc. Quote
Other Factors to Note
In the second quarter of fiscal 2023, Mesa Laboratories witnessed strong bookings growth in its Sterilization and Disinfection Control segment. The segment also benefited from improving labor-based constraints in its Bozeman, MT facility. Management had confirmed during the fiscal second-quarter earnings release that strong execution of process improvement initiatives in commercial engagement, labor supply and supply-chain execution had driven its strong revenue growth and profitability improvements in the quarter. This momentum is expected to have continued in the to-be-reported quarter, thereby driving up the overall revenues.
However, the current unstable macroeconomic business environment, resulting from the supply-chain constraints, unfavorable currency movement and inflationary pressures, is likely to have weighed on the company’s fiscal third-quarter revenues, raising our apprehension.
The Estimate Picture
For third-quarter fiscal 2023, the Zacks Consensus Estimate of $57.7 million for total revenues implies an improvement of 5.5% from the prior-year quarter’s reported figure.
The consensus estimate for earnings per share is pegged at $2.10 , indicating an uptick of 54.4% from the prior-year period’s reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here, as you can see:
Earnings ESP: Mesa Laboratories has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few other medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle:
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has an Earnings ESP of +1.32% and a Zacks Rank of 2. ZBH has an estimated long-term growth rate of 7.7%.
Zimmer Biomet’s earnings surpassed estimates in three of the trailing four quarters and missed the same in the other, with the average surprise being 6.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +5.75% and is a Zacks #2 Rank stock. CAH has an estimated long-term growth rate of 11.7%.
Cardinal Health’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, with the average surprise being 3%.
IDEXX Laboratories, Inc. (IDXX - Free Report) has an Earnings ESP of +0.39% and carries a Zacks Rank of 2 at present. IDXX has an estimated long-term growth rate of 17.3%.
IDEXX’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 5.2%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.